APG-2449 alone or with PLD for advanced cancers
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either a specific type of lung cancer (ALK/ROS1 positive) or advanced solid tumors (Part A), or you are a woman with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum-based chemo (Part B).
- You have at least one tumor that can be measured on a scan.
- You are still able to get around and take care of yourself (ECOG score 0 or 1).
- You have not had a FAK inhibitor before, and you do not have active cancer in your brain or spinal cord.
- You are willing to provide a tumor tissue sample (from a past surgery or a new biopsy) before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
This Phase 1 trial tests APG-2449, a new drug, in people with advanced solid tumors—especially certain lung cancers that have ALK or ROS1 gene fusions. Because it’s an early safety-and-dose study, it may help learn how well the drug works and what doses are safe.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug called APX-343A, either by itself or in combination with the immunotherapy pembrolizumab, for people with advanced solid tumors that have not responded to prior treatments.
This trial tests a new drug called AK112 combined with chemotherapy or another drug (olaparib) for people with ovarian cancer that came back more than 6 months after platinum treatment. The goal is to see if these combinations work better than current options.
This trial tests a new drug called IBI354 against standard chemotherapy for people with ovarian, primary peritoneal, or fallopian tube cancer that stopped responding to platinum-based treatments. It aims to see if the new drug works better and has fewer side effects.
Hear when a new Platinum-resistant Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.